期刊
FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.621043
关键词
Zika virus; Dengue virus; neutralizing antibody; monoclonal antibody; vaccine; therapeutics
类别
资金
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-18-2-0040]
- U.S. Department of Defense (DOD) [W81XWH-18-2-0040]
The unprecedented Zika outbreak in the Americas from 2015-2016 led to global concern and accelerated the deployment of vaccine and therapeutic countermeasures. Several potent neutralizing antibodies against Zika and related flaviviruses have been discovered in recent years. Structure-based approaches have helped identify species-specific and cross-protective epitopes with therapeutic value.
The unprecedented 2015-2016 Zika outbreak in the Americas sparked global concern and drove the rapid deployment of vaccine and therapeutic countermeasures against this re-emerging pathogen. Alongside vaccine development, a number of potent neutralizing antibodies against Zika and related flaviviruses have been identified in recent years. High-throughput antibody isolation approaches have contributed to a better understanding of the B cell responses elicited following infection and/or vaccination. Structure-based approaches have illuminated species-specific and cross-protective epitopes of therapeutic value. This review will highlight previously described monoclonal antibodies with the best therapeutic potential against ZIKV and related flaviviruses, and discuss their implications for the rational design of better vaccine strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据